• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by GreenLight Biosciences Holdings PBC (Amendment)

    7/26/23 4:03:55 PM ET
    $GRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRNA alert in real time by email
    SC 13D/A 1 ea182381-13da1contin_green.htm AMENDMENT NO. 1 TO SCHEDULE 13D

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

     

     

    SCHEDULE 13D/A

     

    (Rule 13d-101)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO

     

    § 240.13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a)

     

    (Amendment No. 1)*

     

     

      

    Greenlight Biosciences Holdings, PBC
    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)

     

    39536G105
    (CUSIP Number)

     

    Continental Grain Company

    767 Fifth Avenue, 15th Floor

    New York, NY 10153-0015

    212-207-5100

     

    Attention:

    Michael Mayberry, General Counsel

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    July 24, 2023
    (Date of Event Which Requires Filing of this Statement)

     

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-l(e), 240.13d-l(f) or 240.13d-l(g), check the following box. ☐

     

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240 13d-7 for other parties to whom copies are to be sent.

     

     

     

    1The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    *information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes’).

     

     

     

     

     

     

    1.        

    Names of Reporting Persons

     

    Continental Grain Company

    2.        

    Check The Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☒   (b) ☐

    3.        

    SEC Use Only

     

     

    4.        

    Source of Funds

     

    WC

    5.        

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     

    6.        

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares
    Beneficially Owned
    By Each Reporting
    Person With
    7.        

    Sole Voting Power

     

    0

    8.        

    Shared Voting Power

     

    0

    9.        

    Sole Dispositive Power

     

    0

    10.     

    Shared Dispositive Power

     

    0

    11.     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0

    12.     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ☐

     

     

    13.     

    Percent of Class Represented by Amount in Row (9)

     

    0.0%

    14.     

    Type of Reporting Person (See Instructions)

     

    CO

     

    1

     

     

    1.        

    Names of Reporting Persons

     

    Conti Greenlight Investors, L.P.

    2.        

    Check The Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☒   (b) ☐

    3.        

    SEC Use Only

     

     

    4.        

    Source of Funds

     

    WC

    5.        

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     

    6.        

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares
    Beneficially Owned
    By Each Reporting
    Person With
    7.        

    Sole Voting Power

     

    0

    8.        

    Shared Voting Power

     

    0

    9.        

    Sole Dispositive Power

     

    0

    10.     

    Shared Dispositive Power

     

    0

    11.     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0

    12.     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ☐

     

     

    13.     

    Percent of Class Represented by Amount in Row (9)

     

    0.0%

    14.     

    Type of Reporting Person (See Instructions)

     

    PN

      

    2

     

     

    1.        

    Names of Reporting Persons

     

    Conti Greenlight LLC

    2.        

    Check The Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☒   (b) ☐

    3.        

    SEC Use Only

     

     

    4.        

    Source of Funds

     

    WC

    5.        

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     

    6.        

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares
    Beneficially Owned
    By Each Reporting
    Person With
    7.        

    Sole Voting Power

     

    0

    8.        

    Shared Voting Power

     

    0

    9.        

    Sole Dispositive Power

     

    0

    10.     

    Shared Dispositive Power

     

    0

    11.     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0

    12.     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ☐

     

     

    13.     

    Percent of Class Represented by Amount in Row (9)

     

    0.0%

    14.     

    Type of Reporting Person (See Instructions)

     

    OO

     

    3

     

     

    This Amendment No. 1 to the statement on Schedule 13D amends and supplements the statement on Schedule 13D filed by the Reporting Persons on June 8, 2023 (the “Original Schedule 13D”, and together with this Amendment No.1, the “Schedule 13D” or the “Statement”). Except as amended herein, the Original Schedule 13D remains in full force and effect. Terms defined in the Original Schedule 13D are used herein as so defined.

     

    The information set forth in response to each separate Item below shall be deemed to be a response to all Items where such information is relevant.

     

    Item 5. Interest in Securities of the Issuer.

     

    Item 5(e) of the Original Schedule 13D is hereby amended and restated as follows:

     

    (e) Date ceased to be a 5% owner. In connection with consummation of the Offer and the Merger in accordance with the Merger Agreement, on July 24, 2023, the Reporting Persons disposed of all previously reported shares of Common Stock pursuant to the Contribution and Exchange Agreement and ceased to beneficially own, or be part of a 13(d) group that beneficially owns, more than five percent of the Common Stock.

     

    4

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: July 26, 2023

     

      Continental Grain Company
       
      /s/ David Dryerman
      Name: David Dryerman
      Title: SVP-Finance and Treasurer
       
      Conti Greenlight Investors, L.P.
       
      By: Conti Greenlight LLC
      Its: General Partner
       
      By: Continental Grain Company
      Its: Managing Member
       
      /s/ Ari Gendason
      Name:  Ari Gendason
      Title: Chief Investment Officer
       
      Conti Greenlight LLC
       
      By: Continental Grain Company
      Its: Managing Member
       
      /s/ Ari Gendason
      Name:  Ari Gendason
      Title: Chief Investment Officer

     

     

    5

     

    Get the next $GRNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRNA

    DatePrice TargetRatingAnalyst
    12/8/2022$4.00Buy
    Canaccord Genuity
    10/14/2022$5.50Outperform
    Credit Suisse
    More analyst ratings

    $GRNA
    Financials

    Live finance-specific insights

    See more
    • GreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding Shares

      LEXINGTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) ("GreenLight" or the "Company") today announced that it is initiating the final steps in closing its previously announced merger with SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc ("Parent"). Following the completion of the Merger, shares of GreenLight common stock are expected to cease trading on the NASDAQ Global Market ("NASDAQ") after market close on July 20, 2023, and will no longer be listed for trading on the NASDAQ. Merger Sub's tender offer (the "Offer") to purchase any and all outstanding shares of GreenLight's common stock (other than shares of GreenLight common stock (

      7/20/23 8:06:08 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Kodiak Venture Partners Iii Lp

      4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

      7/27/23 10:55:29 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider Kodiak Venture Partners Iii Lp claimed ownership of 9,809,895 shares

      3 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

      7/27/23 10:48:26 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Clarke Dennis A.

      4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

      7/27/23 10:25:48 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GreenLight Announces Completion of Merger with Fall Line Endurance Fund

      LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) ("GreenLight" or the "Company") today announced the closing of its previously announced merger with SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc. ("Parent"), pursuant to which Merger Sub merged with and into GreenLight with GreenLight surviving as a wholly-owned subsidiary of Parent (the "Merger"). Following the completion of the Merger, shares of GreenLight common stock, par value $0.0001 per share, and GreenLight warrants ceased trading on the NASDAQ Global Market (the "NASDAQ") before market open on July 24, 2023, and will no longer be listed for trading on the NASDAQ. Each r

      7/24/23 9:49:15 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding Shares

      LEXINGTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) ("GreenLight" or the "Company") today announced that it is initiating the final steps in closing its previously announced merger with SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc ("Parent"). Following the completion of the Merger, shares of GreenLight common stock are expected to cease trading on the NASDAQ Global Market ("NASDAQ") after market close on July 20, 2023, and will no longer be listed for trading on the NASDAQ. Merger Sub's tender offer (the "Offer") to purchase any and all outstanding shares of GreenLight's common stock (other than shares of GreenLight common stock (

      7/20/23 8:06:08 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lifshitz Law PLLC Announces Investigations of GRNA, AAIC, EMBK, and REUN

      NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of GRNA to a group of buyers led by Fall Line Capital, LLC for $0.30 per share in cash. If you are a GRNA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Arlington Asset Investment Corp. (NYSE:AAIC) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connect

      6/3/23 8:17:00 PM ET
      $AAIC
      $EMBK
      $GRNA
      $REUN
      Real Estate Investment Trusts
      Real Estate
      Computer Software: Prepackaged Software
      Technology

    $GRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on GreenLight Biosciences with a new price target

      Canaccord Genuity initiated coverage of GreenLight Biosciences with a rating of Buy and set a new price target of $4.00

      12/8/22 9:11:51 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Credit Suisse initiated coverage on GreenLight Biosciences with a new price target

      Credit Suisse initiated coverage of GreenLight Biosciences with a rating of Outperform and set a new price target of $5.50

      10/14/22 7:27:11 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by GreenLight Biosciences Holdings PBC (Amendment)

      SC 13D/A - GreenLight Biosciences Holdings, PBC (0001822691) (Subject)

      7/28/23 4:25:26 PM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by GreenLight Biosciences Holdings PBC (Amendment)

      SC 13D/A - GreenLight Biosciences Holdings, PBC (0001822691) (Subject)

      7/28/23 10:54:08 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by GreenLight Biosciences Holdings PBC (Amendment)

      SC 13D/A - GreenLight Biosciences Holdings, PBC (0001822691) (Subject)

      7/27/23 4:24:26 PM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRNA
    SEC Filings

    See more
    • SEC Form 15-12G filed by GreenLight Biosciences Holdings PBC

      15-12G - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)

      8/11/23 9:00:27 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GreenLight Biosciences Holdings PBC filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (Amendment)

      8-K/A - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)

      7/28/23 9:02:32 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by GreenLight Biosciences Holdings PBC

      EFFECT - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)

      7/26/23 12:15:07 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care